Alzheimer’s disease

Feb 12, 2025

Alzheimer’s disease has become one of the most pressing global health challenges, with its prevalence rising dramatically over the past few years. As the aging population grows, so does the burden of this neurodegenerative disorder, placing immense strain on healthcare systems worldwide. The Alzheimer's drug market...

Feb 12, 2025

Alzheimer’s disease currently affects an estimated 50 million people worldwide. This number is projected to rise to 75 million by 2030 and a staggering 131.5 million by 2050, according to Alzheimer's Disease International, spanning all age groups globally. While the exact cause of Alzheimer’s disease remains elusiv...

Feb 12, 2025

Alzheimer's disease continues to pose a significant challenge to global healthcare systems, with the 7MM reporting approximately 16 million diagnosed prevalent cases in 2023. This rising AD prevalence highlights an urgent need for innovative treatments to mitigate the growing disease burden on both patients and car...

Feb 12, 2025

Alzheimer’s disease is the most common type of dementia, accounting for more than 60% of all cases, and is characterized by a gradual decline in cognitive and functional abilities. It represents a global health crisis that is increasing with the increasing geriatric population. It represents a global health crisis ...

Jan 28, 2025

FDA Approves LEQEMBI® (Lecanemab-Irmb) IV Maintenance Dosing for Early Alzheimer’s Disease Treatment Eisai Co., Ltd. and Biogen Inc. announced that the FDA has approved the Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab-irmb), allowing intravenous (IV) maintenance dosing every four week...

Jan 07, 2025

Chimerix Submits Dordaviprone NDA for Accelerated Approval to FDA for Recurrent H3 K27M-Mutant Diffuse Glioma Chimerix announced the submission of a NDA to the FDA for dordaviprone. The application seeks accelerated approval for the treatment of recurrent H3 K27M-mutant diffuse glioma, a rare and aggressive brai...

Dec 04, 2024

Biochips, small devices that integrate biological materials and electronic components, have revolutionized healthcare by enabling rapid, precise, and cost-effective diagnostic and therapeutic solutions. These microdevices combine microfluidics, biosensors, and nanotechnology to analyze and manipulate biological inf...

Nov 19, 2024

The 17th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, held in Madrid from October 29 to November 1, 2024, set the stage for groundbreaking updates in Alzheimer’s research, as pharmaceutical leaders presented their latest findings on novel therapies and cutting-edge clinical trials. With an ever-growing...

Jul 30, 2024

The FDA Advisory Committee Considers the AEGEAN Phase III Trial Data in their Review of IMFINZI for Treating Resectable NSCLC The FDA's Oncologic Drugs Advisory Committee (ODAC) acknowledged that AstraZeneca’s IMFINZI (durvalumab) achieved the primary endpoint of event-free survival (EFS) in resectable non-small...

Jul 08, 2024

The world of Alzheimer’s disease treatment witnessed a groundbreaking moment recently as the FDA approved Eli Lilly’s donanemab, marketed as KISUNLA. This new drug brings hope to millions of patients and their families struggling with this debilitating disease. Let us delve into the fascinating journey of donanemab...